LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 4 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $70 | -11.4% | 59,700 | +6.8% | 0.00% | – |
| Q2 2023 | $79 | -99.8% | 55,900 | +143.0% | 0.00% | – |
| Q4 2020 | $40,000 | -90.7% | 23,000 | -95.0% | 0.00% | – |
| Q3 2020 | $432,000 | +0.9% | 460,806 | -6.3% | 0.00% | – |
| Q2 2020 | $428,000 | +92.8% | 491,700 | +83.2% | 0.00% | – |
| Q1 2020 | $222,000 | – | 268,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $28,160,000 | 3.29% |
| Defender Capital, LLC. | 4,416,590 | $3,657,000 | 2.67% |
| Prescott General Partners LLC | 1,851,851 | $1,534,000 | 0.13% |
| Laidlaw Wealth Management LLC | 107,379 | $89,000 | 0.06% |
| Northeast Financial Consultants Inc | 523,756 | $434,000 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $37,000 | 0.04% |
| DAFNA Capital Management LLC | 95,000 | $79,000 | 0.03% |
| Summit X, LLC | 30,700 | $25,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 529,039 | $438,000 | 0.01% |
| Keudell/Morrison Wealth Management | 10,105 | $8,000 | 0.01% |